

## AmpliPhi Biosciences to Hold Business Update Conference Call on May 15

SAN DIEGO--([BUSINESS WIRE](#))--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update conference call on Monday, May 15, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call:	U.S.	877-866-5534
	International	346-406-0930
	Passcode	20313217

Live  
Webcast: [AmpliPhi IR Website](#)

The webcast replay will be available approximately 2 hours after completion of the call and will be archived for 30 days.

Replay:	U.S.	855-859-2056
	International	404-537-3406
	Passcode	20313217

The replay will be available for 48 hours starting approximately 2 hours after completion of the call.

### About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of *S. aureus* in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

## CONTACT:

At the Company:  
AmpliPhi Biosciences  
Matthew Dansey, (858) 800-4869  
[md@ampliphbio.com](mailto:md@ampliphbio.com)  
or  
Investor Relations:  
LHA  
Jody Cain, (310) 691-7100  
[jcain@lhai.com](mailto:jcain@lhai.com)

---

<https://investor.armatapharma.com/2017-05-11-AmpliPhi-Biosciences-to-Hold-Business-Update-Conference-Call-on-May-15>